Mon, Dec 29, 2014
A A A
Welcome Guest
Free Trial RSS
Get FREE trial access to our award winning publications
Alternative Market Briefing

The matter of hedge fund fees

Thursday, November 11, 2010

Benedicte Gravrand, Opalesque Europe.

There was much debate about hedge fund fees at Terrapinn's Hedge 2010 London conference on Tuesday. The 2 and 20 structure has become norm over the past years and has been brought into question since 2008, when most hedge funds failed to deliver what the high fees were for, that is, uncorrelated returns.

Opalesque is here reporting commentaries from Millennium's Israel Englander and GLC's Caroline Hoare, as well as from some major investors.

Izzy on fees "Is the power shifting back to the hedge fund manager?" asked Israel Englander, Chairman and CEO of Millennium Management, at the conference. "My response is; it is not about the transfer of power... For twenty years, nothing has changed; we get paid on performance."

Englander said that Millennium, which is head-quartered in New York, had been adding a lot of transparency for its investors of late. The firm has also increased controls and oversights (they now do two audits each year), invested in state-of-the-art technology, and built a strong management team to help run the place. Englander, who switched from trading to management, enjoys getting out more, and not spending entire days in front of computer screens. "We also have an Investor Day," he added.

Twenty years a......................

To view our full article Click here

Today's Exclusives Today's Other Voices More Exclusives
Previous Opalesque Exclusives                                  
More Other Voices
Previous Other Voices                                               
Access Alternative Market Briefing


  • Top Forwarded
  • Top Tracked
  • Top Searched
  1. Hong Kong-Shanghai stock link fails to live up to expectation so far[more]

    Komfie Manalo, Opalesque Asia: In a report, Reuters said that demand has been subdued with the bulk of activities coming from short-term speculative investors. Las

  2. Investing - Hedge funds get boost from healthcare in 2014, Paulson & Co takes stake in Salix on heels of inventory issues[more]

    Hedge funds get boost from healthcare in 2014 From Valuewalk.com: The healthcare sector started the year on a turbulent note, as stocks of many major biotechnology companies were battered. However, most of the players in this sector have bounced back. The BarclayHedge Healthcare & Biotec

  3. North America - Why Steve Cohen, Connecticut hedge fund billionaire, gives so much in New York[more]

    From Insidephilantrophy.com: Billionaire Steve Cohen was born in Great Neck, New York before attending Wharton, working on Wall Street and then founding SAC Capital Advisors in Connecticut. Though his company (Point72) and foundation are based in Connecticut, Cohen and Alexandra are deeply connected

  4. Investing - Soros buys a highly speculative biotech in the third quarter[more]

    From Fool.com: …The Soros Fund bought 25,000 shares of the struggling small-cap biopharma Aegerion Pharmaceuticals in the third quarter. For those of you who haven't heard of this name, suffice to say that this was a surprising buy in light of the company's recent problems and poor outlook going for

  5. CFTC Revokes Registrations of Illinois Resident Aleks A. Kins and Chicago-based AlphaMetrix, LLC[more]

    Matthias Knab, Opalesque: The U.S. Commodity Futures Trading Commission (CFTC) today announced that it has revoked the registration of Aleks A. Kins of Chicago, Illinois, as an Associated Person and the registrations of AlphaMetrix, LLC (AlphaMetrix), a Delaware limited liability company with its